Professor Gerard discusses recent clinical trials including the TME and CRO7 trials that have shown the importance of preoperative radiotherapy in reducing relapse rate and the STAR trial that has shown the benefits of combining of chemotherapy and radiotherapy, escalating the radiotherapy dose to 50 Gy and that capecitabine should be used without oxaliplatin when treating T3 and T4 tumours.